Evaluation of spinosad for the oral treatment and control of flea infestations on cats in Europe

Methods An ectoparasiticide containing spinosad was evaluated as an oral formulation for cats. Two European laboratory studies and a European multicentre field efficacy and safety study assessed the use of a chewable tablet formulation of spinosad at a dose range of 50–75 mg/kg for treatment and con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Veterinary record open 2014, Vol.1 (1), p.e000047-n/a
Hauptverfasser: Franc, M., Bouhsira, E., Böhm, C., Wolken, S., Wolf, O., Löhlein, W., Wiseman, S., Hayes, B., Schnitzler, B., Fisher, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 1
container_start_page e000047
container_title Veterinary record open
container_volume 1
creator Franc, M.
Bouhsira, E.
Böhm, C.
Wolken, S.
Wolf, O.
Löhlein, W.
Wiseman, S.
Hayes, B.
Schnitzler, B.
Fisher, M.
description Methods An ectoparasiticide containing spinosad was evaluated as an oral formulation for cats. Two European laboratory studies and a European multicentre field efficacy and safety study assessed the use of a chewable tablet formulation of spinosad at a dose range of 50–75 mg/kg for treatment and control of flea infestations on cats. Results The studies with experimentally infested cats consistently demonstrated persistent activity against Ctenocephalides felis with >98 per cent efficacy at four weeks post-treatment. In the field study with naturally infested client-owned cats from 18 clinics across Germany and Italy, two monthly doses of spinosad were administered; selamectin was the comparator product. Safety was evaluated in 226 cats, each receiving at least one dose of spinosad or selamectin; both products were well tolerated. 113 spinosad-treated cats and 71 selamectin-treated cats showed >97 per cent reductions in geometric mean flea counts within 14 days post-treatment and at 60 days post-treatment efficacy was >98 per cent in both groups. Analysis of success rates showed 96 per cent in spinosad-treated cats compared with 90.9 per cent in selamectin-treated cats at day 60. The spinosad tablets were successfully administered to over 98 percent of cats. These studies indicate that this formulation of spinosad is safe and efficacious for treatment and prevention of flea infestations in cats.
doi_str_mv 10.1136/vetreco-2014-000047
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4562449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1715916449</sourcerecordid><originalsourceid>FETCH-LOGICAL-b3807-a92cb1f7b38e154fba6a027ef0a459187d426ac8f70afb14aada4231dda2bf283</originalsourceid><addsrcrecordid>eNqNkV9L5DAUxcOirKJ-goUl4Isv1STNNO2LsAx1FYQBUV-zt22ydmiT2aQd8dvvHTsO6pN5yb_fPfdcDiE_ODvnPM0u1mYIpvaJYFwmDJdU38ihYDORZAjsvTsfkJMYl4hgHU9z9Z0ciCwtRK6KQ_KnXEM3wtB6R72lcdU6H6Gh1gc6PBnqA3QUW8HQGzdQcA2tvRuC7za47QzQ1lkTh1eJSFGmhiHiIy3H4FfmmOxb6KI52e5H5OGqvJ9fJ7eL3zfzX7dJleZMJVCIuuJW4c3wmbQVZMCEMpaBnBU8V40UGdS5VQxsxSVAA1KkvGlAVFbk6RG5nHRXY9Wbpka3aF2vQttDeNEeWv3xx7VP-q9faznLhJQFCpxtBYL_N-JEum9jbboOnPFj1FxxNJJN6OkndOnH4HA8pHKJTkWeIZVOVB18jMHYnRnO9CZEvQ1Rb0LUU4hY9fP9HLuat8gQuJqA57YzL1_R1I93C_FY3t-V88XmedfpfBKq-uWXrP0HvcW_Ng</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784426286</pqid></control><display><type>article</type><title>Evaluation of spinosad for the oral treatment and control of flea infestations on cats in Europe</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Franc, M. ; Bouhsira, E. ; Böhm, C. ; Wolken, S. ; Wolf, O. ; Löhlein, W. ; Wiseman, S. ; Hayes, B. ; Schnitzler, B. ; Fisher, M.</creator><creatorcontrib>Franc, M. ; Bouhsira, E. ; Böhm, C. ; Wolken, S. ; Wolf, O. ; Löhlein, W. ; Wiseman, S. ; Hayes, B. ; Schnitzler, B. ; Fisher, M.</creatorcontrib><description>Methods An ectoparasiticide containing spinosad was evaluated as an oral formulation for cats. Two European laboratory studies and a European multicentre field efficacy and safety study assessed the use of a chewable tablet formulation of spinosad at a dose range of 50–75 mg/kg for treatment and control of flea infestations on cats. Results The studies with experimentally infested cats consistently demonstrated persistent activity against Ctenocephalides felis with &gt;98 per cent efficacy at four weeks post-treatment. In the field study with naturally infested client-owned cats from 18 clinics across Germany and Italy, two monthly doses of spinosad were administered; selamectin was the comparator product. Safety was evaluated in 226 cats, each receiving at least one dose of spinosad or selamectin; both products were well tolerated. 113 spinosad-treated cats and 71 selamectin-treated cats showed &gt;97 per cent reductions in geometric mean flea counts within 14 days post-treatment and at 60 days post-treatment efficacy was &gt;98 per cent in both groups. Analysis of success rates showed 96 per cent in spinosad-treated cats compared with 90.9 per cent in selamectin-treated cats at day 60. The spinosad tablets were successfully administered to over 98 percent of cats. These studies indicate that this formulation of spinosad is safe and efficacious for treatment and prevention of flea infestations in cats.</description><identifier>ISSN: 2052-6113</identifier><identifier>ISSN: 2399-2050</identifier><identifier>EISSN: 2052-6113</identifier><identifier>DOI: 10.1136/vetreco-2014-000047</identifier><identifier>PMID: 26392879</identifier><language>eng</language><publisher>England: British Veterinary Association</publisher><subject>Animals ; Cats ; Ectoparasites ; Field study ; Fleas ; Food ; Insecticides ; Laboratories ; Regulatory approval</subject><ispartof>Veterinary record open, 2014, Vol.1 (1), p.e000047-n/a</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>British Veterinary Association 2013. Re-use permitted under CC BY-NC 4.0</rights><rights>Copyright: 2014 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b3807-a92cb1f7b38e154fba6a027ef0a459187d426ac8f70afb14aada4231dda2bf283</citedby><cites>FETCH-LOGICAL-b3807-a92cb1f7b38e154fba6a027ef0a459187d426ac8f70afb14aada4231dda2bf283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562449/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562449/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,4010,11543,27904,27905,27906,46033,46457,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26392879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Franc, M.</creatorcontrib><creatorcontrib>Bouhsira, E.</creatorcontrib><creatorcontrib>Böhm, C.</creatorcontrib><creatorcontrib>Wolken, S.</creatorcontrib><creatorcontrib>Wolf, O.</creatorcontrib><creatorcontrib>Löhlein, W.</creatorcontrib><creatorcontrib>Wiseman, S.</creatorcontrib><creatorcontrib>Hayes, B.</creatorcontrib><creatorcontrib>Schnitzler, B.</creatorcontrib><creatorcontrib>Fisher, M.</creatorcontrib><title>Evaluation of spinosad for the oral treatment and control of flea infestations on cats in Europe</title><title>Veterinary record open</title><addtitle>Vet Rec Open</addtitle><description>Methods An ectoparasiticide containing spinosad was evaluated as an oral formulation for cats. Two European laboratory studies and a European multicentre field efficacy and safety study assessed the use of a chewable tablet formulation of spinosad at a dose range of 50–75 mg/kg for treatment and control of flea infestations on cats. Results The studies with experimentally infested cats consistently demonstrated persistent activity against Ctenocephalides felis with &gt;98 per cent efficacy at four weeks post-treatment. In the field study with naturally infested client-owned cats from 18 clinics across Germany and Italy, two monthly doses of spinosad were administered; selamectin was the comparator product. Safety was evaluated in 226 cats, each receiving at least one dose of spinosad or selamectin; both products were well tolerated. 113 spinosad-treated cats and 71 selamectin-treated cats showed &gt;97 per cent reductions in geometric mean flea counts within 14 days post-treatment and at 60 days post-treatment efficacy was &gt;98 per cent in both groups. Analysis of success rates showed 96 per cent in spinosad-treated cats compared with 90.9 per cent in selamectin-treated cats at day 60. The spinosad tablets were successfully administered to over 98 percent of cats. These studies indicate that this formulation of spinosad is safe and efficacious for treatment and prevention of flea infestations in cats.</description><subject>Animals</subject><subject>Cats</subject><subject>Ectoparasites</subject><subject>Field study</subject><subject>Fleas</subject><subject>Food</subject><subject>Insecticides</subject><subject>Laboratories</subject><subject>Regulatory approval</subject><issn>2052-6113</issn><issn>2399-2050</issn><issn>2052-6113</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNkV9L5DAUxcOirKJ-goUl4Isv1STNNO2LsAx1FYQBUV-zt22ydmiT2aQd8dvvHTsO6pN5yb_fPfdcDiE_ODvnPM0u1mYIpvaJYFwmDJdU38ihYDORZAjsvTsfkJMYl4hgHU9z9Z0ciCwtRK6KQ_KnXEM3wtB6R72lcdU6H6Gh1gc6PBnqA3QUW8HQGzdQcA2tvRuC7za47QzQ1lkTh1eJSFGmhiHiIy3H4FfmmOxb6KI52e5H5OGqvJ9fJ7eL3zfzX7dJleZMJVCIuuJW4c3wmbQVZMCEMpaBnBU8V40UGdS5VQxsxSVAA1KkvGlAVFbk6RG5nHRXY9Wbpka3aF2vQttDeNEeWv3xx7VP-q9faznLhJQFCpxtBYL_N-JEum9jbboOnPFj1FxxNJJN6OkndOnH4HA8pHKJTkWeIZVOVB18jMHYnRnO9CZEvQ1Rb0LUU4hY9fP9HLuat8gQuJqA57YzL1_R1I93C_FY3t-V88XmedfpfBKq-uWXrP0HvcW_Ng</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Franc, M.</creator><creator>Bouhsira, E.</creator><creator>Böhm, C.</creator><creator>Wolken, S.</creator><creator>Wolf, O.</creator><creator>Löhlein, W.</creator><creator>Wiseman, S.</creator><creator>Hayes, B.</creator><creator>Schnitzler, B.</creator><creator>Fisher, M.</creator><general>British Veterinary Association</general><general>Blackwell Publishing Ltd</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2014</creationdate><title>Evaluation of spinosad for the oral treatment and control of flea infestations on cats in Europe</title><author>Franc, M. ; Bouhsira, E. ; Böhm, C. ; Wolken, S. ; Wolf, O. ; Löhlein, W. ; Wiseman, S. ; Hayes, B. ; Schnitzler, B. ; Fisher, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b3807-a92cb1f7b38e154fba6a027ef0a459187d426ac8f70afb14aada4231dda2bf283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Cats</topic><topic>Ectoparasites</topic><topic>Field study</topic><topic>Fleas</topic><topic>Food</topic><topic>Insecticides</topic><topic>Laboratories</topic><topic>Regulatory approval</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Franc, M.</creatorcontrib><creatorcontrib>Bouhsira, E.</creatorcontrib><creatorcontrib>Böhm, C.</creatorcontrib><creatorcontrib>Wolken, S.</creatorcontrib><creatorcontrib>Wolf, O.</creatorcontrib><creatorcontrib>Löhlein, W.</creatorcontrib><creatorcontrib>Wiseman, S.</creatorcontrib><creatorcontrib>Hayes, B.</creatorcontrib><creatorcontrib>Schnitzler, B.</creatorcontrib><creatorcontrib>Fisher, M.</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Wiley Online Library Open Access</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary record open</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Franc, M.</au><au>Bouhsira, E.</au><au>Böhm, C.</au><au>Wolken, S.</au><au>Wolf, O.</au><au>Löhlein, W.</au><au>Wiseman, S.</au><au>Hayes, B.</au><au>Schnitzler, B.</au><au>Fisher, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of spinosad for the oral treatment and control of flea infestations on cats in Europe</atitle><jtitle>Veterinary record open</jtitle><addtitle>Vet Rec Open</addtitle><date>2014</date><risdate>2014</risdate><volume>1</volume><issue>1</issue><spage>e000047</spage><epage>n/a</epage><pages>e000047-n/a</pages><issn>2052-6113</issn><issn>2399-2050</issn><eissn>2052-6113</eissn><abstract>Methods An ectoparasiticide containing spinosad was evaluated as an oral formulation for cats. Two European laboratory studies and a European multicentre field efficacy and safety study assessed the use of a chewable tablet formulation of spinosad at a dose range of 50–75 mg/kg for treatment and control of flea infestations on cats. Results The studies with experimentally infested cats consistently demonstrated persistent activity against Ctenocephalides felis with &gt;98 per cent efficacy at four weeks post-treatment. In the field study with naturally infested client-owned cats from 18 clinics across Germany and Italy, two monthly doses of spinosad were administered; selamectin was the comparator product. Safety was evaluated in 226 cats, each receiving at least one dose of spinosad or selamectin; both products were well tolerated. 113 spinosad-treated cats and 71 selamectin-treated cats showed &gt;97 per cent reductions in geometric mean flea counts within 14 days post-treatment and at 60 days post-treatment efficacy was &gt;98 per cent in both groups. Analysis of success rates showed 96 per cent in spinosad-treated cats compared with 90.9 per cent in selamectin-treated cats at day 60. The spinosad tablets were successfully administered to over 98 percent of cats. These studies indicate that this formulation of spinosad is safe and efficacious for treatment and prevention of flea infestations in cats.</abstract><cop>England</cop><pub>British Veterinary Association</pub><pmid>26392879</pmid><doi>10.1136/vetreco-2014-000047</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2052-6113
ispartof Veterinary record open, 2014, Vol.1 (1), p.e000047-n/a
issn 2052-6113
2399-2050
2052-6113
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4562449
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection
subjects Animals
Cats
Ectoparasites
Field study
Fleas
Food
Insecticides
Laboratories
Regulatory approval
title Evaluation of spinosad for the oral treatment and control of flea infestations on cats in Europe
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T07%3A03%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20spinosad%20for%20the%20oral%20treatment%20and%20control%20of%20flea%20infestations%20on%20cats%20in%20Europe&rft.jtitle=Veterinary%20record%20open&rft.au=Franc,%20M.&rft.date=2014&rft.volume=1&rft.issue=1&rft.spage=e000047&rft.epage=n/a&rft.pages=e000047-n/a&rft.issn=2052-6113&rft.eissn=2052-6113&rft_id=info:doi/10.1136/vetreco-2014-000047&rft_dat=%3Cproquest_pubme%3E1715916449%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784426286&rft_id=info:pmid/26392879&rfr_iscdi=true